The overall objectives of this BETRNet Research Center (RC) are: 1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biological understanding of key observations made by our clinical researchers; 3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC; 4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC; 5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.
Barrett's Esophagus, Esophageal Neoplasm
The overall objectives of this BETRNet Research Center (RC) are: 1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biological understanding of key observations made by our clinical researchers; 3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC; 4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC; 5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
-
Johns Hopkins Hospital, Baltimore, Maryland, United States, 21205
Mayo Clinic, Rochester, Minnesota, United States, 55905
Washington University School of Medicine, Saint Louis, Missouri, United States, 63110
Columbia University Medical Center, New York, New York, United States, 10032
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27599
University Hospitals of Cleveland, Cleveland, Ohio, United States, 44106-8066
Cleveland Clinic, Cleveland, Ohio, United States, 44195
University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104
VA Puget Sound Health Care System, Seattle, Washington, United States, 98108
Fred Hutchinson Cancer Research Center, UWMC, Seattle, Washington, United States, 98109
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
Yes
Case Western Reserve University,
Amitabh Chak, MD, PRINCIPAL_INVESTIGATOR, University Hospitals Cleveland Medical Center, CWRU, Cleveland, OH
Gary W Falk, MD, MS, PRINCIPAL_INVESTIGATOR, University of Pennsylvania
William Grady, MD, PRINCIPAL_INVESTIGATOR, Fred Hutchinson Cancer Research Center, UWMC, Seattle, WA
Nicholas J Shaheen, M.D., PRINCIPAL_INVESTIGATOR, University of North Carolina, Chapel Hill
Ganapathy Prasad, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic
Marcia Canto, M.D., PRINCIPAL_INVESTIGATOR, Johns Hopkins University
John Dumont, D.O., PRINCIPAL_INVESTIGATOR, University Hospitals Cleveland Medical Center
Prashanthi Thota, M.D., PRINCIPAL_INVESTIGATOR, The Cleveland Clinic
Jean Wang, MD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine
Julian Abrams, MD, PRINCIPAL_INVESTIGATOR, Columbia University
Andrew Kaz, MD, PRINCIPAL_INVESTIGATOR, VA Puget Sound Health Care System
2028-07-31